The secondary metabolites of higher plants include diverse chemicals, such as alkaloids, isoprenoids and phenolic compounds (phenylpropanoids and flavonoids), which are produced from primary metabolites such as amino acids or [acetyl-CoA](#annotation-3){ref-type="annotation"} ([Supplementary Fig. S1](#S1){ref-type="supplementary-material"}). Although these compounds are widely used in human health and nutrition, at present they are mainly obtained by extraction from plants. However, extraction yields are low because most of these metabolites accumulate at low levels in plant cells. There have been many attempts to use plant metabolic engineering to increase the amounts of secondary metabolites. However, it is very difficult to obtain the desired products because of the complex and strict regulation of their biosynthesis. Chemical synthesis has also been used to produce plant secondary metabolites; however, the complexity and chirality of these compounds have hampered the development of cost-effective methods.

Recently, there has been increasing interest in microbial production of plant secondary metabolites by reconstructing their biosynthetic pathways in microorganisms[@b1][@b2][@b3][@b4][@b5]. Among these metabolites, isoprenoids are produced from [acetyl-CoA](#annotation-4){ref-type="annotation"} in the mevalonate pathway or [glyceraldehyde-3-phosphate](#annotation-5){ref-type="annotation"} and [pyruvic acid](#annotation-6){ref-type="annotation"} in the 1-deoxy-[D]{.smallcaps}-xylulose-5-phosphate pathway ([Supplementary Fig. S1](#S1){ref-type="supplementary-material"}). The biosynthesis of isoprenoids is well characterized, and they have been produced by microbes in a simple growth medium[@b6]. The other major groups of secondary metabolites, that is, alkaloids and phenolic compounds, are derived from aromatic amino acids ([Supplementary Fig. S1](#S1){ref-type="supplementary-material"}). These compounds can be produced via microbial fermentation, but such systems require the addition of expensive precursor chemicals[@b7][@b8][@b9], which makes these methods commercially unfeasible. Production of alkaloids and phenolic compounds from an inexpensive and readily available material has been one of the most important challenges for metabolic engineering of secondary metabolites[@b10][@b11].

Alkaloids are low-molecular-weight, nitrogen-containing compounds that are found in \~20% of plant species. They are very important in medicine because of their high biological activities. Most alkaloids are derived from amines produced by the decarboxylation of amino acids, such as [histidine](#annotation-7){ref-type="annotation"}, [lysine](#annotation-8){ref-type="annotation"}, [ornithine](#annotation-9){ref-type="annotation"}, [tryptophan](#annotation-10){ref-type="annotation"} and [tyrosine](#annotation-11){ref-type="annotation"}. One of the largest and most diverse groups of pharmaceutically important alkaloids is the benzylisoquinoline alkaloids (BIAs). BIAs, which include the analgesic compounds [morphine](#annotation-12){ref-type="annotation"} and [codeine](#annotation-13){ref-type="annotation"} and the antibacterial agents [berberine](#annotation-14){ref-type="annotation"} and [palmatine](#annotation-15){ref-type="annotation"}, are produced through [(S)-reticuline](#annotation-16){ref-type="annotation"} from [L-tyrosine](#annotation-17){ref-type="annotation"}. Thus, [(S)-reticuline](#annotation-18){ref-type="annotation"} is a main branch-point intermediate in the biosynthesis of many types of BIAs, and also acts as a non-narcotic building block that is useful in the development of novel antimalarial and anticancer drugs. In this study, we focused on the fermentative production of [(S)-reticuline](#annotation-19){ref-type="annotation"} in *Escherichia coli* grown in a simple medium without additional substrates.

Here we constructed a bacterial platform for plant alkaloid production from simple carbon sources. In this platform, a tailor-made alkaloid biosynthetic pathway from [L-tyrosine](#annotation-20){ref-type="annotation"} was constructed in [L-tyrosine](#annotation-21){ref-type="annotation"} over-producing *E. coli* cells. The recombinant strain could produce 46.0 mg l^−1^ of [(S)-reticuline](#annotation-22){ref-type="annotation"} from [glycerol](#annotation-23){ref-type="annotation"}, suggesting that the fermentation platform would enable low-cost production of many diverse alkaloids.

Results
=======

Design of an artificial BIA biosynthetic pathway
------------------------------------------------

We have already succeeded in synthesizing [reticuline](#annotation-24){ref-type="annotation"} from [dopamine](#annotation-25){ref-type="annotation"}[@b7]. Thus, to obtain BIAs from a simple medium without the addition of [dopamine](#annotation-26){ref-type="annotation"}, there are two additional steps that must be introduced: fermentative production of [L-tyrosine](#annotation-27){ref-type="annotation"} and conversion of [L-tyrosine](#annotation-28){ref-type="annotation"} to [dopamine](#annotation-29){ref-type="annotation"}. We first generated an *E. coli* strain that over-produces [L-tyrosine](#annotation-30){ref-type="annotation"} by amino-acid fermentation. This was accomplished by three steps of genetic engineering. An *E. coli* strain has disrupted the *tyrR* gene, the product of which represses the expression of genes involved in aromatic amino-acid biosynthesis[@b12]. In addition, the feedback-inhibition-resistant (fbr) 3-deoxy-[D]{.smallcaps}-arabino-heptulosonate-7-phosphate (DAHP) synthase (fbr-DAHPS: *aroG*^*fbr*^) and fbr-chorismate mutase/prephenate dehydrogenase (fbr-CM/PDH: *tyrA*^*fbr*^) are overexpressed in the shikimic acid pathway[@b13]. To increase metabolic flow into the shikimic acid pathway, phosphoenolpyruvate synthetase (PEPS: *ppsA*) and transketolase (TKT: *tktA*)[@b14] are exogenously introduced ([Fig. 1](#f1){ref-type="fig"}). Thus, the [L-tyrosine](#annotation-31){ref-type="annotation"} over-producing *E. coli* strain contains a knockout mutation in *tyrR* and a plasmid expressing the *aroG*^*fbr*^, *tyrA*^*fbr*^, *ppsA* and *tktA* genes ([Supplementary Fig. S2](#S1){ref-type="supplementary-material"}). The engineered *E. coli* cells produced [L-tyrosine](#annotation-32){ref-type="annotation"} in the medium at a yield of \~4.37±0.17 g l^−1^ (24.0±0.94 mM; average yield±standard deviation from three independent experiments), when [glycerol](#annotation-33){ref-type="annotation"} was used as the carbon source. The overall yield of [L-tyrosine](#annotation-34){ref-type="annotation"}, when [glycerol](#annotation-35){ref-type="annotation"} was used as a carbon source, was 29.5% (molar ratio). By contrast, the wild-type *E. coli* cells produced low quantities of [L-tyrosine](#annotation-36){ref-type="annotation"} in culture.

The BIA synthetic pathway of plants has not been completely elucidated. The pathway to [dopamine](#annotation-37){ref-type="annotation"} or [4-hydroxyphenylacetaldehyde](#annotation-38){ref-type="annotation"} ([4-HPAA](#annotation-39){ref-type="annotation"}) from [L-tyrosine](#annotation-40){ref-type="annotation"} is proposed in [Figure 2](#f2){ref-type="fig"}, but not all of the enzymes have been identified as yet. We originally designed an artificial pathway of [reticuline](#annotation-41){ref-type="annotation"} synthesis using microbial enzymes. In plants and animals, [L-DOPA](#annotation-42){ref-type="annotation"} is mainly synthesized from [L-tyrosine](#annotation-43){ref-type="annotation"} by tyrosine hydroxylase (EC 1.14.16.2); however, [tetrahydrobiopterin](#annotation-44){ref-type="annotation"} ([BH4](#annotation-45){ref-type="annotation"}) is required as a cofactor for this reaction. *E. coli* cannot synthesize [BH4](#annotation-46){ref-type="annotation"}; therefore, to convert [L-tyrosine](#annotation-47){ref-type="annotation"} to [L-DOPA](#annotation-48){ref-type="annotation"}, we chose tyrosinase (TYR; EC 1.14.18.1), which is unrelated to BIA biosynthesis. The TYRs from humans, *Pholiota nameko* and *Streptomyces castaneoglobisporus* were expressed in *E. coli* cells, and we examined their ability to convert [L-tyrosine](#annotation-49){ref-type="annotation"} into [L-DOPA](#annotation-50){ref-type="annotation"}. Only the TYR from *S. castaneoglobisporus* (ScTYR) successfully converted [L-tyrosine](#annotation-51){ref-type="annotation"} into [L-DOPA](#annotation-52){ref-type="annotation"}, and did not require unique cofactors other than copper and an adaptor protein (ORF378)[@b15][@b16]. When the selected TYR was expressed in the [L-tyrosine](#annotation-53){ref-type="annotation"} over-producing *E. coli* strain, [L-DOPA](#annotation-54){ref-type="annotation"} was produced in the medium at a yield of 293±5.9 mg l^−1^. The conversion efficiency from [L-tyrosine](#annotation-55){ref-type="annotation"} to [L-DOPA](#annotation-56){ref-type="annotation"} was 6.19±0.13%.

In our synthetic pathway, [dopamine](#annotation-57){ref-type="annotation"} was synthesized from [L-DOPA](#annotation-58){ref-type="annotation"} by the decarboxylation reaction ([Fig. 1](#f1){ref-type="fig"}). It is important that only [L-DOPA](#annotation-59){ref-type="annotation"} undergoes decarboxylation. If other aromatic amines were produced by decarboxylation, monoamine oxidase (MAO; EC 1.4.3.4) would act on these amines to produce their corresponding aldehydes, which could then be accepted in the coupling reaction catalysed by norcoclaurine synthase (NCS; EC 4.2.1.78). Because MAO shows greater activity towards [tyramine](#annotation-60){ref-type="annotation"} than [dopamine](#annotation-61){ref-type="annotation"}, it was important to select an enzyme that specifically decarboxylates [L-DOPA](#annotation-62){ref-type="annotation"}, not [L-tyrosine](#annotation-63){ref-type="annotation"}; otherwise, MAO would act on [tyramine](#annotation-64){ref-type="annotation"} produced by the decarboxylation of [L-tyrosine](#annotation-65){ref-type="annotation"}, and the resulting [4-HPAA](#annotation-66){ref-type="annotation"} could then be accepted in the coupling reaction with [dopamine](#annotation-67){ref-type="annotation"} catalysed by NCS. The coupling product, [(S)-norcoclaurine](#annotation-68){ref-type="annotation"}, is converted to [(S)-N-methylcoclaurine](#annotation-69){ref-type="annotation"} by norcoclaurine 6-*O*-methyltransferase (6OMT) and coclaurine-*N*-methyltransferase (CNMT). Because 3′-hydroxy-*N*-methylcoclaurine-4′-*O*-methyltransferase (4′OMT) has no ability to catalyse [(S)-N-methylcoclaurine](#annotation-70){ref-type="annotation"}[@b17], the synthetic flow constructed in the cells terminated at [(S)-N-methylcoclaurine](#annotation-71){ref-type="annotation"} because of the lack of cytochrome P450 hydroxylase (CYP80B) in our system ([Figs 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}). In the plant BIA biosynthetic pathway, tyrosine/DOPA decarboxylase (EC 4.1.1.25) catalyses the decarboxylation of [L-tyrosine](#annotation-72){ref-type="annotation"} and [L-DOPA](#annotation-73){ref-type="annotation"} to [tyramine](#annotation-74){ref-type="annotation"} and [dopamine](#annotation-75){ref-type="annotation"}, respectively[@b18] ([Fig. 2](#f2){ref-type="fig"}). For this reason, we selected the [L]{.smallcaps}-DOPA-specific decarboxylase (DODC; EC 4.1.1.28) from *Pseudomonas putida* strain KT2440, which exhibited a more than 10^3^-fold preference for [L-DOPA](#annotation-76){ref-type="annotation"} than for other aromatic amino acids (Koyanagi T. *et al*., in preparation). When the selected TYR and DODC were expressed in the [L-tyrosine](#annotation-77){ref-type="annotation"} over-producing *E. coli* strain, [dopamine](#annotation-78){ref-type="annotation"} was produced in the medium at a yield of \~260±22.7 mg l^−1^. The conversion efficiency from [L-tyrosine](#annotation-79){ref-type="annotation"} to [dopamine](#annotation-80){ref-type="annotation"} was 7.08±0.62%, which was slightly improved compared with that from [L-tyrosine](#annotation-81){ref-type="annotation"} to [L-DOPA](#annotation-82){ref-type="annotation"}. The amount of melanin-like pigment in the culture medium of a [dopamine](#annotation-83){ref-type="annotation"}-producing strain was lower than that in a [L-DOPA](#annotation-84){ref-type="annotation"}-producing strain ([Supplementary Fig. S3](#S1){ref-type="supplementary-material"}). It was suggested that [L-DOPA](#annotation-85){ref-type="annotation"} was converted into [dopamine](#annotation-86){ref-type="annotation"} by DODC before the reaction of [L-DOPA](#annotation-87){ref-type="annotation"} into [dopaquinone](#annotation-88){ref-type="annotation"}. The *Km* value for [L-DOPA](#annotation-89){ref-type="annotation"} of ScTYR was 8.1 mM (ref. [@b15]). By contrast, the *Km* value for [L-DOPA](#annotation-90){ref-type="annotation"} of *P. putida* DODC was 0.092 mM (Koyanagi T. *et al*., in preparation). It was indicated that *P. putida* DODC dominates ScTYR in the reaction of [L-DOPA](#annotation-91){ref-type="annotation"}, and the combination of TYR and DODC enables the conversion of [L-tyrosine](#annotation-92){ref-type="annotation"} to [dopamine](#annotation-93){ref-type="annotation"} with reducing [dopaquinone](#annotation-94){ref-type="annotation"} formation.

In the final step of the fermentative production of [(S)-reticuline](#annotation-95){ref-type="annotation"}, we combined the [dopamine](#annotation-96){ref-type="annotation"}-producing pathway described above with the synthetic pathway from [dopamine](#annotation-97){ref-type="annotation"} to [(S)-reticuline](#annotation-98){ref-type="annotation"}[@b7]. The genes encoding NCS and MAO were inserted into the pET-21d vector together with the genes for TYR and DODC. The genes for 6OMT, 4′OMT and CNMT were inserted into the pACYC184 vector ([Supplementary Fig. S2](#S1){ref-type="supplementary-material"}). The natural biosynthetic pathway in plants is not necessarily suitable for a microbial production system; therefore, our designed synthetic pathway differs from the original biosynthetic pathway. We carefully designed and optimized an artificial BIA pathway consisting of genes that were unrelated to the natural biosynthetic pathway ([Fig. 1](#f1){ref-type="fig"}). The newly designed pathway comprises one *E. coli* gene knockout, four overexpressed genes and eight exogenous genes. Our system uses selected enzymes to construct a single pathway from [L-tyrosine](#annotation-99){ref-type="annotation"} to [(S)-norlaudanosoline](#annotation-100){ref-type="annotation"}. This system circumvents the complicated branched pathway and a potentially problematic CYP reaction in bacteria ([Figs 1](#f1){ref-type="fig"} and [2](#f2){ref-type="fig"}).

[(S)-Reticuline](#annotation-101){ref-type="annotation"} production from a simple carbon source
-----------------------------------------------------------------------------------------------

Liquid chromatography--mass spectrometry (LC--MS) analysis showed that engineered *E. coli* cells produced up to 2.26 mg l^−1^ (average of 2.00±0.28 mg l^−1^ from three independent experiments) [(S)-reticuline](#annotation-102){ref-type="annotation"} from [glucose](#annotation-103){ref-type="annotation"} in the culture medium ([Fig. 3a,b](#f3){ref-type="fig"}). Without [glucose](#annotation-104){ref-type="annotation"}, the yield of [(S)-reticuline](#annotation-105){ref-type="annotation"} was low (80 μg l^−1^), indicating that [(S)-reticuline](#annotation-106){ref-type="annotation"} was derived from a simple carbon source, [glucose](#annotation-107){ref-type="annotation"}. The amount of [(S)-reticuline](#annotation-108){ref-type="annotation"} production was reduced to one-quarter in the wild-type *E. coli* cells with the synthetic pathway from [L-tyrosine](#annotation-109){ref-type="annotation"} to [(S)-reticuline](#annotation-110){ref-type="annotation"}. This result confirmed that metabolic engineering of the aromatic amino-acid pathway effectively produced secondary metabolites from a simple carbon source. The growth rate of recombinant *E. coli* cells indicated that the intermediates in the reticuline biosynthetic pathway or [(S)-reticuline](#annotation-111){ref-type="annotation"} did not inhibit the growth of *E. coli* cells. In this system, [(S)-reticuline](#annotation-112){ref-type="annotation"} was produced by leaky expression of biosynthetic genes without induction by [isopropyl-β-D-thiogalactoside](#annotation-113){ref-type="annotation"} ([IPTG](#annotation-114){ref-type="annotation"}; [Fig. 3c](#f3){ref-type="fig"}), which substantially reduces production costs. When [glycerol](#annotation-115){ref-type="annotation"} was used as the carbon source, [(S)-reticuline](#annotation-116){ref-type="annotation"} production increased up to 6.24 mg l^−1^ (average of 5.92±0.36 mg l^−1^ from three independent experiments) within 80 h ([Fig. 3d](#f3){ref-type="fig"}), which was three times higher than the amount produced in the [glucose](#annotation-117){ref-type="annotation"}-based medium. It was reported that [glycerol](#annotation-118){ref-type="annotation"} is a more suitable carbon source than [glucose](#annotation-119){ref-type="annotation"} for the production of [shikimic acid](#annotation-120){ref-type="annotation"} and [L-phenylalanine](#annotation-121){ref-type="annotation"}[@b19][@b20]. Therefore, it is likely that [glycerol](#annotation-122){ref-type="annotation"} is also a more suitable carbon source for BIA production, as is the case for other products related to the shikimic acid pathway. The conversion efficiency from [L-tyrosine](#annotation-123){ref-type="annotation"} to [(S)-reticuline](#annotation-124){ref-type="annotation"} was 0.150±0.01%, which is much lower than that for [dopamine](#annotation-125){ref-type="annotation"}. To investigate the low conversion efficiency of [(S)-reticuline](#annotation-126){ref-type="annotation"} production, the amount of intermediate compounds, the expression levels of the biosynthetic genes (*TYR*, *ORF378*, *DODC*, *MAO*, *NCS*, *6OMT*, *CNMT* and *4′OMT*), and the degradation of [dopamine](#annotation-127){ref-type="annotation"}, [norlaudanosoline](#annotation-128){ref-type="annotation"} and [(S)-reticuline](#annotation-129){ref-type="annotation"} in culture were examined. [L-Tyrosine](#annotation-130){ref-type="annotation"} was not increased during growth, and other intermediate compounds ([L-DOPA](#annotation-131){ref-type="annotation"}, [dopamine](#annotation-132){ref-type="annotation"} and intermediated BIAs) were not observed in the culture medium ([Supplementary Fig. S4](#S1){ref-type="supplementary-material"}), indicating that metabolic flow to [reticuline](#annotation-133){ref-type="annotation"} was not interrupted. Reverse transcription PCR (RT--PCR) results indicated that all biosynthetic genes were expressed ([Fig. 4](#f4){ref-type="fig"}). The expression levels of plant genes (*NCS*, *6OMT*, *CNMT* and *4′OMT*) were low compared with microbial genes. The expression level of *DODC* was higher than that of *TYR*, which enables the conversion of [L-DOPA](#annotation-134){ref-type="annotation"} to [dopamine](#annotation-135){ref-type="annotation"}. The degradation analysis was carried out by adding substrates at a concentration close to that of the production yield to the culture medium. As a result, [dopamine](#annotation-136){ref-type="annotation"} and [norlaudanosoline](#annotation-137){ref-type="annotation"} were much more unstable than [reticuline](#annotation-138){ref-type="annotation"} ([Supplementary Fig. S5](#S1){ref-type="supplementary-material"}). These observations, together with the fact that intermediated compounds were not accumulated ([Supplementary Fig. S4](#S1){ref-type="supplementary-material"}), indicated that the low yield of [(S)-reticuline](#annotation-139){ref-type="annotation"} from [dopamine](#annotation-140){ref-type="annotation"} was attributed to the instability of [dopamine](#annotation-141){ref-type="annotation"} and [norlaudanosoline](#annotation-142){ref-type="annotation"}, and to a lesser extent, the inefficient conversion of [L-tyrosine](#annotation-143){ref-type="annotation"} to [L-DOPA](#annotation-144){ref-type="annotation"}. The increase in expression levels of plant genes could improve the usage efficiency of [dopamine](#annotation-145){ref-type="annotation"} and [norlaudanosoline](#annotation-146){ref-type="annotation"}. Although TYR catalyses the oxidation of [L-tyrosine](#annotation-147){ref-type="annotation"} to [L-DOPA](#annotation-148){ref-type="annotation"}, TYR also has the ability to convert [L-DOPA](#annotation-149){ref-type="annotation"} or [dopamine](#annotation-150){ref-type="annotation"} to its quinone derivative (*o*-diphenolase), which is easily oxidized and polymerizes to form a melanin pigment. In our system, a melanin-like pigment was produced in the culture medium ([Supplementary Fig. S3](#S1){ref-type="supplementary-material"}). Therefore, we speculated that the instability of intermediate compounds might be attributed to *o*-diphenolase activity via TYR reactions. It has been reported that TYR from *Ralstonia solanacearum* (RsTYR) possesses low *o*-diphenolase activity[@b21]. This report prompted us to integrate RsTYR into our platform instead of ScTYR. As expected, the platform containing RsTYR produced up to 46 mg l^−1^ (average of 40.5±4.8 mg l^−1^ from three independent experiments) of [reticuline](#annotation-151){ref-type="annotation"}, a yield approximately seven times higher than the platform using ScTYR ([Fig. 3d](#f3){ref-type="fig"}). Because the [dopamine](#annotation-152){ref-type="annotation"}-producing strain using RsTYR produced 1.05±0.05 g l^−1^ (6.85±0.30 mM) of [dopamine](#annotation-153){ref-type="annotation"}, a yield almost four times higher than the [dopamine](#annotation-154){ref-type="annotation"}-producing strain using ScTYR, the increased production ability of [dopamine](#annotation-155){ref-type="annotation"} might contribute to increased [reticuline](#annotation-156){ref-type="annotation"} production.

Although NCS is an (*S*)-form specific enzyme, [reticuline](#annotation-157){ref-type="annotation"} was produced as a racemate in our previous system[@b7] because of a spontaneous condensation reaction involving [dopamine](#annotation-158){ref-type="annotation"} and [3,4-dihydroxyphenylacetaldehyde](#annotation-159){ref-type="annotation"} to form [(R,S)-norlaudanosoline](#annotation-160){ref-type="annotation"}. The newly constructed system produced the (*S*)-form exclusively ([Fig. 3e,f](#f3){ref-type="fig"}). Furthermore, even when NCS was absent from our platform, which produced [(R,S)-norlaudanosoline](#annotation-161){ref-type="annotation"} by a spontaneous condensation reaction, [(R)-reticuline](#annotation-162){ref-type="annotation"} could not be detected ([Fig. 5a,b](#f5){ref-type="fig"}). According to analysis of the [reticuline](#annotation-163){ref-type="annotation"} production system from [norlaudanosoline](#annotation-164){ref-type="annotation"}, [(R)-reticuline](#annotation-165){ref-type="annotation"} was detected only when a small amount of [norlaudanosoline](#annotation-166){ref-type="annotation"} was added to the culture ([Fig. 5c--f](#f5){ref-type="fig"}). These results led us to speculate that [(S)-reticuline](#annotation-167){ref-type="annotation"} accumulates because methyltransferases (6OMT, CNMT and 4′OMT) react to the (*S*)-form in a superior manner to the (*R*)-form, or that the (*R*)-form ceases to be modified or degraded in *E. coli* cells. A larger amount of [norlaudanosoline](#annotation-168){ref-type="annotation"} was available for [reticuline](#annotation-169){ref-type="annotation"} production in our new platform compared with the [dopamine](#annotation-170){ref-type="annotation"}-adding system[@b7]; therefore, production of [(R)-reticuline](#annotation-171){ref-type="annotation"} was not observed in the newly constructed platform. The fermentative system developed in this study can produce optically active [(S)-reticuline](#annotation-172){ref-type="annotation"} rapidly (that is, in a few days) compared with fermentation systems using cultured plant cells or transgenic plants (months to years).

The fermentation strategy for secondary metabolites described here requires cultivation of engineered cells in simple growth medium without additional substrates. Therefore, this system will drastically reduce the costs of producing scarce secondary metabolites. The [glucose](#annotation-173){ref-type="annotation"} or [glycerol](#annotation-174){ref-type="annotation"} used in this system is inexpensive and readily available, compared with the additional substrates that were required in previous microbial systems, such as [dopamine](#annotation-175){ref-type="annotation"} or [norlaudanosoline](#annotation-176){ref-type="annotation"}[@b7][@b8]. Although the overall yield of [(S)-reticuline](#annotation-177){ref-type="annotation"} in this system was low, we estimate that the production cost of [(S)-reticuline](#annotation-178){ref-type="annotation"} using this method would be much lower than that of previous microbial systems in terms of substrate costs. In addition to reduced production costs, another advantage of this system is the simple and effective purification procedure, which results in [(S)-reticuline](#annotation-179){ref-type="annotation"} with little contamination by other undesired BIAs. [(S)-Reticuline](#annotation-180){ref-type="annotation"} was purified from the culture medium using solid-phase extraction and high-performance liquid chromatography (HPLC; [Supplementary Fig. S6](#S1){ref-type="supplementary-material"}). This procedure recovered more than 90% of purified [(S)-reticuline](#annotation-181){ref-type="annotation"} in two steps. A simple purification procedure resulting in high yields makes this production system economically viable.

Discussion
==========

In plants, the secondary metabolite biosynthetic pathway is branched, complicated and difficult to reconstruct in a microbial production system. In this study, we first demonstrated the feasibility of fermentative production of a plant alkaloid from a simple carbon source, using selected enzymes to construct a tailor-made biosynthetic pathway in an [L-tyrosine](#annotation-182){ref-type="annotation"} over-producing *E. coli* strain. We succeeded in [(S)-reticuline](#annotation-183){ref-type="annotation"} production by converting [L-tyrosine](#annotation-184){ref-type="annotation"} to [dopamine](#annotation-185){ref-type="annotation"} with a combination of selected TYR and DODC, and constructing a synthetic pathway from [dopamine](#annotation-186){ref-type="annotation"} to a BIA skeleton using microbial MAO. [(S)-Reticuline](#annotation-187){ref-type="annotation"} is contained at low amount in natural plant, because it is an intermediated compound in BIA biosynthetic pathway. It was reported that [(S)-reticuline](#annotation-188){ref-type="annotation"} accumulated at high level in latex of transgenic opium poppy, which has antisense berberine bridge enzyme gene[@b22]. The amount of [(S)-reticuline](#annotation-189){ref-type="annotation"} accumulation was estimated \~320 mg per 1 l of latex over 60 days[@b22][@b23]. In the case of our platform, [(S)-reticuline](#annotation-190){ref-type="annotation"} accumulated about 40 mg per 1 l of culture medium within 3 days. In general, extraction of chemical compounds from plant sources has some problems, such as time cost, troublesome for collecting, difficult scale-up procedure. It was suggested that our bacterial platform would be more suitable for [reticuline](#annotation-191){ref-type="annotation"} production than extraction procedure from plant sources.

In our system, we produced [(S)-reticuline](#annotation-192){ref-type="annotation"}, which is a branch-point intermediate in the biosynthesis of many types of BIAs. Therefore, our bacterial platform can be used to produce [(S)-reticuline](#annotation-193){ref-type="annotation"} derivatives by chemosynthesis from [(S)-reticuline](#annotation-194){ref-type="annotation"} or by transforming the engineered strain with biosynthetic genes required for the target compound. Recently, two key enzymes in the morphine biosynthetic pathway, thebaine 6-*O*-demethylase and codeine *O*-demethylase, have been identified[@b24]. Therefore, the biosynthetic genes in the morphine biosynthetic pathway from [(R)-reticuline](#annotation-195){ref-type="annotation"} to [morphine](#annotation-196){ref-type="annotation"} have been isolated and characterized completely. Morphine alkaloids are synthesized from [(S)-reticuline](#annotation-197){ref-type="annotation"} via [(R)-reticuline](#annotation-198){ref-type="annotation"}, which is a two-step isomerization reaction catalysed by 1,2-dehydroreticuline synthase and 1,2-dehydroreticulinium reductase[@b25][@b26]. Although the biosynthetic genes responsible for converting [(S)-reticuline](#annotation-199){ref-type="annotation"} to [(R)-reticuline](#annotation-200){ref-type="annotation"} have not been identified, our [dopamine](#annotation-201){ref-type="annotation"}-adding system is able to produce [reticuline](#annotation-202){ref-type="annotation"} as a racemate by using *E. coli* cells expressing [reticuline](#annotation-203){ref-type="annotation"} biosynthetic genes without NCS[@b7]. In plant secondary metabolism, CYPs are one of the most important groups of biosynthetic enzymes. The expression and function of plant CYPs is potentially problematic in a microbial production system. However, the successful expression of plant CYPs in a microbial host such as *E. coli*, with modification of the amino-terminal region, has recently been reported[@b27]. Including these biosynthetic genes containing CYPs in our microbial fermentation system may achieve production of morphine alkaloids from simple carbon sources by [(R,S)-reticuline](#annotation-204){ref-type="annotation"}.

Furthermore, because bacterial fermentation systems have advanced metabolic engineering for the production of amino acids, our platform could be further developed to produce other secondary metabolites. As an example, [L-phenylalanine](#annotation-205){ref-type="annotation"} and [L-tryptophan](#annotation-206){ref-type="annotation"} were easily over-produced in our system by overexpression of the branched pathway genes (*trp* operon or *pheA*) from chorismate to [L-phenylalanine](#annotation-207){ref-type="annotation"} or [L-tryptophan](#annotation-208){ref-type="annotation"}, respectively[@b28]. Indole alkaloids, which are the most structurally diverse alkaloids along with BIAs, are synthesized from [L-tryptophan](#annotation-209){ref-type="annotation"} and [secologanin](#annotation-210){ref-type="annotation"}, with several biosynthetic genes isolated and characterized[@b5]. The isolation of genes early in the pathway to [secologanin](#annotation-211){ref-type="annotation"} enables our system to be expanded with respect to applications for metabolic engineering of many indole alkaloids ([Supplementary Fig. S1](#S1){ref-type="supplementary-material"}). Various phenolic compounds have been successfully produced from [L-phenylalanine](#annotation-212){ref-type="annotation"} and [L-tyrosine](#annotation-213){ref-type="annotation"} in microbial systems[@b9]. The fermentation system described here is easily applicable for metabolic engineering of phenolic compounds ([Supplementary Fig. S1](#S1){ref-type="supplementary-material"}). Many diverse secondary metabolites are derived from aromatic amino acids or [acetyl-CoA](#annotation-214){ref-type="annotation"}; therefore, the fermentation platform described here illustrates a general strategy of metabolic engineering for the production of secondary metabolites, especially aromatic amino-acid derivatives. Combined with the fermentation platform for the production of isoprenoids[@b6], our platform represents a significant advance in the metabolic engineering of secondary metabolites.

Methods
=======

Materials
---------

All synthetic genes were obtained from GenScript. [(R,S)-Norlaudanosoline](#annotation-215){ref-type="annotation"} was purchased from Acros Organics. [L-Tyrosine](#annotation-216){ref-type="annotation"}, [L-DOPA](#annotation-217){ref-type="annotation"} and [dopamine](#annotation-218){ref-type="annotation"} were purchased from Sigma-Aldrich. (*R*,*S*)-Reticuline was a gift from Mitsui Chemicals.

Construction of expression vectors
----------------------------------

Construction of an *E. coli* strain over-producing [L-tyrosine](#annotation-219){ref-type="annotation"} was achieved by the following steps: disruption of the *tyrR* gene[@b12]; overexpression of fbr-DAHPS (*aroG*^*fbr*^) and fbr-CM/PDH (*tyrA*^*fbr*^) in the shikimic acid pathway[@b13]; and increasing the metabolic flows into the shikimic acid pathway by overexpressing PEPS (*ppsA*) and TKT (*tktA*)[@b14] ([Fig. 1](#f1){ref-type="fig"}). We constructed an expression vector containing *tyrA*^*fbr*^, *aroG*^*fbr*^, *tktA* and *ppsA*. The genes *tyrA*^*fbr*^ and *aroG*^*fbr*^ cloned into pUC57 were purchased from GenScript and *tyrA*^*fbr*^ was flanked by *Nco*I and *Eco*RI restriction enzyme recognition sites, and *aroG*^*fbr*^ was fused to the T7 promoter. An *Eco*RI site was located upstream of the T7 promoter, and a *Sac*I site was located downstream of *aroG*^*fbr*^. The *tktA* and *ppsA* genes were amplified from genomic DNA of *E. coli* K-12 MG1655 using the primer sets NdeI-tktA-F and tktA-XhoI-R, and NdeI-ppsA-F and ppsA-XhoI-R, respectively ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). After digestion with *Nde*I and *Xho*I, *tktA* and *ppsA* were individually cloned into pET-41a (Novagen) and pCOLADuet-1 (Merck), respectively. A DNA fragment containing the *tyrA*^*fbr*^ gene was excised from *tyrA*^*fbr*^/pUC57 using *Nco*I and *Eco*RI, and then cloned into pCOLADuet-1. The *Eco*RI-*Sac*I fragment of *aroG*^*fbr*^/pUC57 was cloned into *tyrA*^*fbr*^/pCOLADuet-1, yielding the *tyrA*^*fbr*^-*aroG*^*fbr*^ expression vector. We amplified *tktA* under the control of the T7 promoter from *tktA*/pET-41a using the primers 5Sac-T7 and 3NottktA ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). These were then cloned into *tyrA*^*fbr*^-*aroG*^*fbr*^/pCOLADuet-1, generating *tyrA*^*fbr*^-*aroG*^*fbr*^-*tktA*/pCOLADuet-1. Finally, we digested *ppsA*/pCOLADuet-1 with *Not*I and *Xho*I to obtain a fragment containing the *ppsA* gene and the T7 promoter. This fragment was then cloned into *tyrA*^*fbr*^-*aroG*^*fbr*^-*tktA*/pCOLADuet-1, yielding *tyrA*^*fbr*^-*aroG*^*fbr*^-*tktA*-*ppsA*/pCOLADuet-1 ([Supplementary Fig. S2](#S1){ref-type="supplementary-material"}), and its sequence was confirmed.

The norlaudanosoline synthetic pathway consists of four enzymes; TYR of *S. castaneoglobisporus* (ScTYR containing TYR and its adaptor protein, ORF378) or RsTYR (*Rcs0337*), DODC of *P. putida*, MAO of *Micrococcus luteus* and NCS of *Coptis japonica*. In this study, we used a codon-optimized *MAO* (opt*MAO*) and cloned it into a pGS-21a plasmid from GenScript. The *MAO* gene used previously (*NCS*-*MAO*/pKK223-3)[@b7] was replaced by opt*MAO* driven by the T7 promoter. This was achieved by integrating the *Bam*HI-*Hind*III fragment of opt*MAO* and the T7 promoter generated by PCR using the primers 5Bam-T7 and 3oMAO ([Supplementary Table S1](#S1){ref-type="supplementary-material"}) into *NCS*-*MAO*/pKK223-3, generating *NCS*-opt*MAO*/pKK223-3. The PCR product for *DODC* (*Nde*I-*Bam*HI fragment, obtained using the primers 5NdeDODC and 3BamDODC ([Supplementary Table S1](#S1){ref-type="supplementary-material"})) was ligated into the cognate site of pET-3a (Novagen). The *DODC* gene with the T7 promoter was amplified from *DODC*/pET-3a with the primers 5BamSacRVT7 and 3BamDODC ([Supplementary Table S1](#S1){ref-type="supplementary-material"}), and cloned into *NCS-optMAO*/pKK223-3. We purchased *ScTYR* or *RsTYR* cloned into pGS-21a from GenScript. The PCR product for *ScTYR* or *RsTYR* (*Sac*I-*Eco*RV fragment, amplified using primers 5SacI-T7 and 3pGSEcoRV ([Supplementary Table S1](#S1){ref-type="supplementary-material"})) was ligated into the cognate site of *NCS*-*DODC*-*optMAO*/pKK223-3 yielding *NCS-TYR-DODC-optMAO*/pKK223-3. To compare production among lines harbouring different plasmid backbones, we generated a pET-21d (Novagen) plasmid-based vector. We amplified the fragment containing the T7 promoter fused to *NCS* from *NCS-MAO*/pKK223-3 (ref. [@b7]) using the primers 5BglII-T7 and 3NCSBamSacRV ([Supplementary Table S1](#S1){ref-type="supplementary-material"}). The fragment was ligated into the *Bgl*II-*Bam*HI site of pET-21d. The *Sac*I-*Hind*III fragment for *NCS*-*DODC*-opt*MAO*/pKK223-3, containing *DODC*-opt*MAO* genes was ligated into NCS/pET-21d, generating *NCS-DODC*-opt*MAO*/pET-21d. Finally, the PCR product for *TYR* was ligated into the *Sac*I-*Eco*RV site of *NCS*-*DODC*-opt*MAO*/pET-21d, yielding *NCS-TYR-DODC*-opt*MAO*/pET-21d ([Supplementary Fig. S2](#S1){ref-type="supplementary-material"}). The line harbouring the pET-21d-based plasmid produced slightly higher levels of [reticuline](#annotation-220){ref-type="annotation"} (0.14 versus 0.11 mg l^−1^ in the small-scale culture); therefore, we selected *NCS-TYR-DODC*-opt*MAO*/pET-21d as the expression plasmid for norlaudanosoline pathway enzymes.

To construct the [L-DOPA](#annotation-221){ref-type="annotation"}-producing strain, the *Nde*I-*Xho*I fragment of *TYR*/pGS-21a was cloned into the cognate site of pET-23a, yielding *TYR*/pET-23a. *TYR* and *DODC* (*Bam*HI fragment of *NCS-TYR-DODC*-opt*MAO*/pET-21d) were cloned into pET-23a, yielding *TYR*-*DODC*/pET-23a.

Construction of aromatic compound-producing strains
---------------------------------------------------

The genetic design of the [L-tyrosine](#annotation-222){ref-type="annotation"} over-producing strain is described by Lütke-Eversloh and Stephanopoulos[@b14]. The markerless deletion of *tyrR*, *tyrR*∷null strain, was constructed by PCR-based method[@b29]. BL21 (DE3) *tyrR*∷null was transformed with *tyrA*^*fbr*^-*aroG*^*fbr*^-*tktA*-*ppsA*/pCOLADuet-1, yielding the [L-tyrosine](#annotation-223){ref-type="annotation"} over-producing strain. To construct the [L-DOPA](#annotation-224){ref-type="annotation"}- and [dopamine](#annotation-225){ref-type="annotation"}-producing strains, the [L-tyrosine](#annotation-226){ref-type="annotation"} over-producing strain was transformed with *TYR*/pET-23a and *TYR*-*DODC*/pET-23a, respectively. To construct the reticuline-producing strain, the [L-tyrosine](#annotation-227){ref-type="annotation"} over-producing strain was transformed with *NCS*-*TYR*-*DODC*-opt*MAO*/pET-21d and *6OMT-4′OMT-CNMT*/pACYC184 (ref. [@b7]; [Supplementary Fig. S2](#S1){ref-type="supplementary-material"}).

Fermentation conditions
-----------------------

Cells were cultured overnight in liquid LB medium at 37 °C, then 10 ml of the cell culture was inoculated into 1 l of modified conventional medium (per litre: 47.6 g Turbo Broth (Athena Enzyme System), 1.6 g [NH4Cl](#annotation-228){ref-type="annotation"}, 2.49 mg [CuSO4·5H2O](#annotation-229){ref-type="annotation"}, 3 g [glucose](#annotation-230){ref-type="annotation"} or 5 g [glycerol](#annotation-231){ref-type="annotation"}, and appropriate antibiotics (50 mg [ampicillin](#annotation-232){ref-type="annotation"}, 25 mg [kanamycin](#annotation-233){ref-type="annotation"} and 50 mg [chloramphenicol](#annotation-234){ref-type="annotation"}). Cultures were grown at 25 °C in a 3-l jar fermenter (BMS-03PI, ABLE). The pH was maintained at 7.1 by automatic addition of 28% [NH4OH](#annotation-235){ref-type="annotation"} and 1 M [HCl](#annotation-236){ref-type="annotation"}. The agitation speed was 100 r.p.m. at the time of inoculation, and dissolved oxygen levels were allowed to fall to 10% of O~2~ saturation with continuous air supply of 1 volume per volume per minute. The [glucose](#annotation-237){ref-type="annotation"} concentration was maintained between 0.1 and 7 g l^−1^ by addition of 0.5 g ml^−1^ [glucose](#annotation-238){ref-type="annotation"} solution. The [glycerol](#annotation-239){ref-type="annotation"} concentration was maintained between 0.1 and 6 g l^−1^ by addition of 1 g ml^−1^ [glycerol](#annotation-240){ref-type="annotation"} solution. If needed, an indicating concentration of [IPTG](#annotation-241){ref-type="annotation"} was added to the culture when OD~600~ reached 10 ([glucose](#annotation-242){ref-type="annotation"}-based medium) or 15 ([glycerol](#annotation-243){ref-type="annotation"}-based medium).

Detection and quantification of chemical compounds
--------------------------------------------------

[Glucose](#annotation-244){ref-type="annotation"} in the culture medium was analysed by the mutarotase-glucose method using a Glucose CII Test Wako (Wako). [Glycerol](#annotation-245){ref-type="annotation"} in the culture medium was analysed using a Glycerol Assay Kit (Cayman Chemical). To analyse aromatic compounds in the culture medium, except for [reticuline](#annotation-246){ref-type="annotation"} and [norlaudanosoline](#annotation-247){ref-type="annotation"}, cultures were collected and treated with 1 N [HCl](#annotation-248){ref-type="annotation"} for solving crystallized [tyrosine](#annotation-249){ref-type="annotation"}. After centrifugation, samples were analysed by HPLC equipped with a Discovery HS F5 column (Supelco). Compounds were separated on the column by increasing the concentration of acetonitrile from 3 to 20% in 10 mM ammonium formate (pH 3.0) at a flow rate of 0.5 ml min^−1^. Elution of compounds was monitored by measuring absorbance at 280 nm.

To measure [reticuline](#annotation-250){ref-type="annotation"} and [norlaudanosoline](#annotation-251){ref-type="annotation"} production, the culture medium was collected at various times, and proteins were precipitated with 2% [trichloroacetate](#annotation-252){ref-type="annotation"}. The supernatant was analysed by LC--MS (3200 Q TRAP, Applied Biosystems Japan) after separation on an Agilent HPLC system (Agilent). The HPLC conditions were as follows: column, TSKgel ODS-80Ts (4.6×250 mm; Tosoh); solvent system, A: 0.1% acetic acid in water, B: 0.1% acetic acid in acetonitrile; gradient modes: 90% A (0--5 min), 90--60% A (5--20 min) and 10% A (20--30 min); flow rate, 0.5 ml min^−1^ at 40 °C. [Reticuline](#annotation-253){ref-type="annotation"} was identified by comparison with authentic [reticuline](#annotation-254){ref-type="annotation"} with regard to the fragmentation spectrum in LC--MS/MS. The amounts of [reticuline](#annotation-255){ref-type="annotation"} and [norlaudanosoline](#annotation-256){ref-type="annotation"} were estimated from standard curves using Analyst 1.4.1 software. Experiments were repeated three times.

The stereoselectivity of [reticuline](#annotation-257){ref-type="annotation"} was analysed by LC--MS after separation on an Agilent HPLC system. HPLC conditions were as follows: column, CHIRALCEL OD-H (4.6×250 mm, Daicel Chemical Industries); solvent system, hexane:2-propanol:diethylamine (72:28:0.1); flow rate, 0.55 ml min^−1^ at 40 °C.

Quantitative RT--PCR analysis of synthetic pathway genes
--------------------------------------------------------

The reticuline-producing strain was grown on [glycerol](#annotation-258){ref-type="annotation"}-based medium in a jar fermenter. [IPTG](#annotation-259){ref-type="annotation"} (50 μM) was added to the culture when OD~600~ reached 15. For total RNA extraction, cells were collected at 40 h post-inoculation. Total RNA was extracted using an RNeasy Mini kit (Qiagen). To eliminate contaminated DNA, we used DNaseI treatment system included in RNAqueous-4PCR Kit (Ambion). A total of 1.5 μg total RNA was used in reverse transcription reactions using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).

Relative RNA concentrations were determined by quantitative RT--PCR using a 7300 Real-time PCR system with TaqMan Gene Expression Assay (Applied Biosystems). Primers and probes were designed using Primer Express 1.5 software (Perkin-Elmer; [Supplementary Table 1](#S1){ref-type="supplementary-material"}). The amount of mRNA was quantified against a standard curve using the *C*~t~ value.

Observation of aromatic compound degradation in culture
-------------------------------------------------------

The reticuline-producing strain was grown at 25 °C in Turbo Broth containing 10 μM of [CuSO4](#annotation-260){ref-type="annotation"} and appropriate antibiotics without sugar. [IPTG](#annotation-261){ref-type="annotation"} (50 μM) was added when OD~600~ reached 10. At 12 h after [IPTG](#annotation-262){ref-type="annotation"} induction, each substrate (final concentration: 0.5, 2 and 8 mM [dopamine](#annotation-263){ref-type="annotation"}, 7.5, 30 and 120 μM [norlaudanosoline](#annotation-264){ref-type="annotation"} or 7.5, 30 and 120 μM [reticuline](#annotation-265){ref-type="annotation"}) was added to the culture. The additive [reticuline](#annotation-266){ref-type="annotation"} was enzymatically synthesized from 0.45 mM of [norlaudanosoline](#annotation-267){ref-type="annotation"} using a crude extract of BL21 (DE3) harbouring *6OMT-4′OMT-CNMT*/pACYC184 (ref. [@b7]). In all experiments, new synthesis of [norlaudanosoline](#annotation-268){ref-type="annotation"}, mono- and di-methylated [norlaudanosoline](#annotation-269){ref-type="annotation"} and [reticuline](#annotation-270){ref-type="annotation"} were not observed.

Purification of [(S)-reticuline](#annotation-271){ref-type="annotation"}
------------------------------------------------------------------------

[(S)-Reticuline](#annotation-272){ref-type="annotation"} was purified from culture medium with an Oasis HLB solid-phase extraction cartridge (Waters) and by HPLC. The cartridge was pre-equilibrated with water before loading the culture medium, washed with 5% methanol, and then [(S)-reticuline](#annotation-273){ref-type="annotation"} eluted with 100% methanol. The eluent was subjected to HPLC equipped with a TSKgel ODS-80Ts column. Peak fractions corresponding to [(S)-reticuline](#annotation-274){ref-type="annotation"} were collected, and the degree of refining confirmed by MS analysis.
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    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

dopaquinone

:   compound

    AHMIDUVKSGCHAU-LURJTMIESA-N

    439316

    388447

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

dopaquinone

:   compound

    AHMIDUVKSGCHAU-LURJTMIESA-N

    439316

    388447

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

shikimic acid

:   compound

    JXOHGGNKMLTUBP-HSUXUTPPSA-N

    8742

    8412

L-phenylalanine

:   compound

    COLNVLDHVKWLRT-QMMMGPOBSA-N

    6140

    5910

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

3,4-dihydroxyphenylacetaldehyde

:   compound

    IADQVXRMSNIUEL-UHFFFAOYSA-N

    119219

    106504

(R,S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-UHFFFAOYSA-N

    18519

    17491

(R,S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-UHFFFAOYSA-N

    18519

    17491

(R)-reticuline

:   compound

    BHLYRWXGMIUIHG-OAHLLOKOSA-N

    440586

    389485

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(R)-reticuline

:   compound

    BHLYRWXGMIUIHG-OAHLLOKOSA-N

    440586

    389485

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(R)-reticuline

:   compound

    BHLYRWXGMIUIHG-OAHLLOKOSA-N

    440586

    389485

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(R)-reticuline

:   compound

    BHLYRWXGMIUIHG-OAHLLOKOSA-N

    440586

    389485

morphine

:   compound

    BQJCRHHNABKAKU-KBQPJGBKSA-N

    5288826

    4450907

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(R)-reticuline

:   compound

    BHLYRWXGMIUIHG-OAHLLOKOSA-N

    440586

    389485

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(R)-reticuline

:   compound

    BHLYRWXGMIUIHG-OAHLLOKOSA-N

    440586

    389485

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(R,S)-reticuline

:   compound

    BHLYRWXGMIUIHG-UHFFFAOYSA-N

    10233

    9816

L-phenylalanine

:   compound

    COLNVLDHVKWLRT-QMMMGPOBSA-N

    6140

    5910

L-tryptophan

:   compound

    QIVBCDIJIAJPQS-VIFPVBQESA-N

    6305

    6066

L-phenylalanine

:   compound

    COLNVLDHVKWLRT-QMMMGPOBSA-N

    6140

    5910

L-tryptophan

:   compound

    QIVBCDIJIAJPQS-VIFPVBQESA-N

    6305

    6066

L-tryptophan

:   compound

    QIVBCDIJIAJPQS-VIFPVBQESA-N

    6305

    6066

secologanin

:   compound

    CSKKDSFETGLMSB-NRZPKYKESA-N

    161276

    141670

secologanin

:   compound

    CSKKDSFETGLMSB-NRZPKYKESA-N

    161276

    141670

L-phenylalanine

:   compound

    COLNVLDHVKWLRT-QMMMGPOBSA-N

    6140

    5910

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

acetyl-coenzyme A

:   compound

    ZSLZBFCDCINBPY-ZSJPKINUSA-N

    444493

    392413

(R,S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-UHFFFAOYSA-N

    18519

    17491

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

L-3,4-dihydroxyphenylalanine

:   compound

    WTDRDQBEARUVNC-LURJTMIESA-N

    6047

    5824

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

ammonium chloride

:   compound

    NLXLAEXVIDQMFP-UHFFFAOYSA-N

    25517

    23807

copper sulfate pentahydrate

:   compound

    JZCCFEFSEZPSOG-UHFFFAOYSA-L

    24463

    22871

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

ampicillin

:   compound

    AVKUERGKIZMTKX-NJBDSQKTSA-N

    6249

    6013

kanamycin

:   compound

    SBUJHOSQTJFQJX-NOAMYHISSA-N

    6032

    5810

chloramphenicol

:   compound

    WIIZWVCIJKGZOK-RKDXNWHRSA-N

    5959

    5744

ammonium hydroxide

:   compound

    VHUUQVKOLVNVRT-UHFFFAOYSA-N

    14923

    14218

hydrochloric acid

:   compound

    VEXZGXHMUGYJMC-UHFFFAOYSA-N

    313

    307

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

hydrochloric acid

:   compound

    VEXZGXHMUGYJMC-UHFFFAOYSA-N

    313

    307

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

trichloroacetate

:   compound

    YNJBWRMUSHSURL-UHFFFAOYSA-N

    6421

    10772050

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

copper sulfate

:   compound

    ARUVKPQLZAKDPS-UHFFFAOYSA-L

    24462

    22870

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

dopamine

:   compound

    VYFYYTLLBUKUHU-UHFFFAOYSA-N

    681

    661

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

erythrose-4-phosphate

:   compound

    NGHMDNPXVRFFGS-IUYQGCFVSA-N

    122357

    109096

erythrose-4-phosphate

:   compound

    NGHMDNPXVRFFGS-IUYQGCFVSA-N

    122357

    109096

4-hydroxyphenylpyruvate

:   compound

    KKADPXVIOXHVKN-UHFFFAOYSA-N

    979

    954

4-hydroxyphenylpyruvate

:   compound

    KKADPXVIOXHVKN-UHFFFAOYSA-N

    979

    954

3,4-dihydroxyphenylacetaldehyde

:   compound

    IADQVXRMSNIUEL-UHFFFAOYSA-N

    119219

    106504

3,4-dihydroxyphenylacetaldehyde

:   compound

    IADQVXRMSNIUEL-UHFFFAOYSA-N

    119219

    106504

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

4-hydroxyphenylacetaldehyde

:   compound

    IPRPPFIAVHPVJH-UHFFFAOYSA-N

    440113

    389113

4-hydroxyphenylacetaldehyde

:   compound

    IPRPPFIAVHPVJH-UHFFFAOYSA-N

    440113

    389113

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

glucose

:   compound

    WQZGKKKJIJFFOK-GASJEMHNSA-N

    5793

    5589

L-tyrosine

:   compound

    OUYCCCASQSFEME-QMMMGPOBSA-N

    6057

    5833

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(R,S)-reticuline

:   compound

    BHLYRWXGMIUIHG-UHFFFAOYSA-N

    10233

    9816

(R,S)-reticuline

:   compound

    BHLYRWXGMIUIHG-UHFFFAOYSA-N

    10233

    9816

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

glycerol

:   compound

    PEDCQBHIVMGVHV-UHFFFAOYSA-N

    753

    733

(R,S)-reticuline

:   compound

    BHLYRWXGMIUIHG-UHFFFAOYSA-N

    10233

    9816

(R,S)-reticuline

:   compound

    BHLYRWXGMIUIHG-UHFFFAOYSA-N

    10233

    9816

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889

(S)-reticuline

:   compound

    BHLYRWXGMIUIHG-HNNXBMFYSA-N

    439653

    388724

isopropyl-β-D-thiogalactoside

:   compound

    BPHPUYQFMNQIOC-NXRLNHOXSA-N

    656894

    571154

(S)-norlaudanosoline

:   compound

    ABXZOXDTHTTZJW-LBPRGKRZSA-N

    439845

    388889
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![Bacterial BIA biosynthetic pathway constructed in *Escherichia coli* cells.\
For [L-tyrosine](#annotation-275){ref-type="annotation"} over-production, four enzymes (TKT, PEPS, fbr-DAHPS and fbr-CM/PDH) are overexpressed. Black box indicates the common aromatic pathway. The tailor-made biosynthetic pathway (blue) consisted of TYR, DODC and MAO. The plant biosynthetic pathway (red) was modified to circumvent the CYP80B reaction. CNMT, coclaurine-*N*-methyltransferase of *Coptis japonica* (GenBank accession number [AB061863](AB061863)); DAHPS, 3-deoxy-[D]{.smallcaps}-arabino-heptulosonate-7-phosphate synthase (*aroG*^*fbr*^, GenBank accession number [J01591](J01591)); DODC, DOPA decarboxylase of *Pseudomonas putida* (GenBank accession number [AE015451](AE015451)); [E4P](#annotation-276){ref-type="annotation"}, [erythrose-4-phosphate](#annotation-277){ref-type="annotation"}; fbr, feedback-inhibition-resistant; fbr-CM/PDH, fbr-chorismate mutase/prephenate dehydrogenase (*tyrA*^*fbr*^, GenBank accession number [M10431](M10431)); [HPP](#annotation-278){ref-type="annotation"}, [4-hydroxyphenylpyruvate](#annotation-279){ref-type="annotation"}; MAO, monoamine oxidase of *Micrococcus luteus* (GenBank accession number [AB010716](AB010716)); NCS, norcoclaurine synthetase of *C. japonica* (GenBank accession number [AB267399](AB267399)); PEPS, phosphoenolpyruvate (PEP) synthetase (*ppsA*, GenBank accession number [X59381](X59381)); TKT, transketolase (*tktA*, GenBank accession number [X68025](X68025)); TYR, tyrosinase of *Streptomyces castaneoglobisporus* (ScTYR containing tyrosinase and its adaptor protein, ORF378, GenBank accession numbers [AY254101](AY254101) and [AY254102](AY254102)) or tyrosinase of *Ralstonia solanacearum* (RsTYR, *Rcs0337*, GenBank accession number [AL646052](AL646052)); [3,4-DHPAA](#annotation-280){ref-type="annotation"}, [3,4-dihydroxyphenylacetaldehyde](#annotation-281){ref-type="annotation"}; 6OMT, norcoclaurine 6-*O*-methyltransferase of *C. japonica* (GenBank accession number [D29811](D29811)); 4′OMT, 3′-hydroxy-*N*-methylcoclaurine 4′-*O*-methyltransferase of *C. japonica* (GenBank accession number [D29812](D29812)).](ncomms1327-f1){#f1}

![Proposed plant biosynthetic pathway and genes involved in the biosynthesis of BIAs from [L-tyrosine](#annotation-282){ref-type="annotation"} to [(S)-reticuline](#annotation-283){ref-type="annotation"}.\
CYP80B, *N*-methylcoclaurine 3′-hydroxylase; NCS, norcoclaurine synthase; TH, tyrosine hydroxylase; TYDC, tyrosine/dopa decarboxylase; [4-HPAA](#annotation-284){ref-type="annotation"}, [4-hydroxyphenylacetaldehyde](#annotation-285){ref-type="annotation"}; 6OMT, norcoclaurine 6-*O*-methyltransferase; 4′OMT, 3′-hydroxy-*N*-methylcoclaurine 4′-*O*-methyltransferase.](ncomms1327-f2){#f2}

![Fermentative production of [(S)-reticuline](#annotation-286){ref-type="annotation"}.\
(**a**) Time course of [(S)-reticuline](#annotation-287){ref-type="annotation"} production in *Escherichia coli* cultures. [L-Tyrosine](#annotation-288){ref-type="annotation"} over-producing *E. coli* (red circles) or wild-type strains (blue squares) harbouring *NCS-ScTYR-DODC*-opt*MAO*/pET-21d and *6OMT-4′OMT-CNMT*/pACYC184 were grown in a jar fermenter. In the case of an [L-tyrosine](#annotation-289){ref-type="annotation"} over-producing strain, the culture was carried out in medium with (red circles) or without [glucose](#annotation-290){ref-type="annotation"} (green triangles). Cell growth (broken lines with the same symbols as those for [(S)-reticuline](#annotation-291){ref-type="annotation"} production) is represented as the optical density at 600 nm. The arrow indicates addition of [IPTG](#annotation-292){ref-type="annotation"} (50 μM) at the indicated time. Data are representative of three independent experiments. (**b**) LC--MS/MS analysis of the reaction product from our system. Selected-ion monitoring (SIM) parameter: *m/z*=330 ([reticuline](#annotation-293){ref-type="annotation"}). (**c**) Effect of [IPTG](#annotation-294){ref-type="annotation"} concentration on fermentative production of [(S)-reticuline](#annotation-295){ref-type="annotation"} in [glucose](#annotation-296){ref-type="annotation"}-based medium. The *E. coli* strain over-producing [L-tyrosine](#annotation-297){ref-type="annotation"} and expressing [reticuline](#annotation-298){ref-type="annotation"} biosynthetic genes was grown until the OD~600~ was 10 before the addition of [IPTG](#annotation-299){ref-type="annotation"} (arrow). No [IPTG](#annotation-300){ref-type="annotation"} induction (blue squares), 50 μM (red circles), 150 μM (green triangles) or 500 μM [IPTG](#annotation-301){ref-type="annotation"} (purple crosses). Data are representative of three independent experiments. (**d**) Fermentative production of [(S)-reticuline](#annotation-302){ref-type="annotation"} in [glycerol](#annotation-303){ref-type="annotation"}-based medium. A reticuline-producing strain using ScTYR (blue squares) or RsTYR (red circles) was cultured. The arrow indicates addition of [IPTG](#annotation-304){ref-type="annotation"} (50 μM) at the indicated time. Cell growth (broken lines with the same symbols as those used for [(S)-reticuline](#annotation-305){ref-type="annotation"} production) is represented as the optical density at 600 nm. The error bar indicates the standard deviation of three independent experiments. (**e**, **f**) Analysis of stereoselectivity of the reaction product towards [(R,S)-reticuline](#annotation-306){ref-type="annotation"}. Authentic [(R,S)-reticuline](#annotation-307){ref-type="annotation"} (**e**) and the reaction product in cultures of *E. coli* cells expressing biosynthetic genes (**f**) were analysed by LC--MS. SIM parameter: *m/z*=330 ([reticuline](#annotation-308){ref-type="annotation"}).](ncomms1327-f3){#f3}

![Relative transcription level of the genes related to the [reticuline](#annotation-309){ref-type="annotation"} production pathway.\
Total RNA was collected from a jar fermenter culture in [glycerol](#annotation-310){ref-type="annotation"}-based Turbo Broth at 40 h post-inoculation. Transcription levels were determined by quantitative real-time PCR. The values represent the number of times the genes are expressed compared with expression of the *TYR* gene (set at 1.00). Results are presented as the average of six repetitions (triplicate reverse transcription reactions from two independent total RNA samples).](ncomms1327-f4){#f4}

![Analysis of stereoselectivity of the reaction product towards [(R,S)-reticuline](#annotation-311){ref-type="annotation"}.\
Authentic [(R,S)-reticuline](#annotation-312){ref-type="annotation"} (**a**), the reaction product in the culture of the reticuline-producing strain without NCS (**b**), the reaction product in the culture of BL21DE3 cells harbouring *6OMT-4*′*OMT-CNMT*/pACYC184 (a plasmid for producing [reticuline](#annotation-313){ref-type="annotation"} from [norlaudanosoline](#annotation-314){ref-type="annotation"}) (**c**--**f**), were analysed by LC--MS. Selected-ion monitoring (SIM) parameter: *m*/*z*=330 ([reticuline](#annotation-315){ref-type="annotation"}). BL21DE3 cells harbouring *6OMT-4*′*OMT-CNMT*/pACYC184 were grown in LB medium at 25 °C until the OD~600~ reached 0.5. Then, 1 mM of [IPTG](#annotation-316){ref-type="annotation"} and the indicated concentration, 10 μM (**c**), 30 μM (**d**), 100 μM (**e**) and 300 μM (**f**) of [norlaudanosoline](#annotation-317){ref-type="annotation"} were added. Samples were collected at 12 h after induction.](ncomms1327-f5){#f5}
